1
|
Bolchini M, Cortinovis M, Zavarise P, Dalla Volta G. Atypical presentation of herpes zoster with cranial neuralgia and nodular skin lesions, a case report. Neurol Sci 2024; 45:2923-2925. [PMID: 38353848 DOI: 10.1007/s10072-024-07387-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Accepted: 02/03/2024] [Indexed: 05/12/2024]
Affiliation(s)
- Marco Bolchini
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo Gualla 15, 25128, Brescia, Italy.
| | - Matteo Cortinovis
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo Gualla 15, 25128, Brescia, Italy
| | - Paola Zavarise
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo Gualla 15, 25128, Brescia, Italy
| | - Giorgio Dalla Volta
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo Gualla 15, 25128, Brescia, Italy
| |
Collapse
|
2
|
Graziani L, Bolchini M, Zavarise P, Dalla Volta G. Simultaneous bilateral intracranial-tract internal carotid artery stenting (CAS), a case report. Acta Neurol Belg 2024; 124:743-746. [PMID: 37644251 DOI: 10.1007/s13760-023-02374-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 08/21/2023] [Indexed: 08/31/2023]
Affiliation(s)
- Lanfroi Graziani
- Interventional Cardiology and Hemodynamics Unit, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Marco Bolchini
- Department of Clinical and Experimental Sciences, University of Brescia, Viale Europa, 11, 25121, Brescia, Italy.
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo, Gualla 15, 25128, Brescia, Italy.
| | - Paola Zavarise
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo, Gualla 15, 25128, Brescia, Italy
| | - Giorgio Dalla Volta
- Neurology Unit, Istituto Clinico Città di Brescia, Via Bartolomeo, Gualla 15, 25128, Brescia, Italy
| |
Collapse
|
3
|
Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G, Sances G, Tassorelli C, Baraldi C, Castro FL, Guerzoni S, Prudenzano MP, Fallacara A, Gentile M, Ornello R, Onofri A, Burgalassi A, Chiarugi A, De Cesaris F, Granato A, Casalena A, De Tommaso M, Mampreso E, Merlo P, Coppola G, Battistini S, Rebecchi V, Rainero I, Sepe FN, Dalla Volta G, Sacco S, Geppetti P, Iannone LF. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study. CNS Drugs 2023; 37:1069-1080. [PMID: 37999868 PMCID: PMC10703741 DOI: 10.1007/s40263-023-01050-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/25/2023] [Indexed: 11/25/2023]
Abstract
BACKGROUND Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few and with limited follow-up. OBJECTIVE We aimed to evaluate the long-term (up to 52 weeks) effectiveness and tolerability of fremanezumab in high-frequency episodic migraine and chronic migraine. METHODS This s an independent, prospective, multicenter cohort study enrolling outpatients in 17 Italian Headache Centers with high-frequency episodic migraine or chronic migraine and multiple preventive treatment failures. Patients were treated with fremanezumab 225 mg monthly. The primary outcomes included changes from baseline (1 month before treatment) in monthly headache days, response rates (reduction in monthly headache days from baseline), and persistence in medication overuse at months 3, 6, and 12 (all outcome timeframes refer to the stated month). Secondary outcomes included changes from baseline in acute medication intake and disability questionnaires scores at the same timepoints. A last observation carried forward analysis was also performed. RESULTS A total of 90 patients who received at least one dose of fremanezumab and with a potential 12-month follow-up were included. Among them, 15 (18.0%) patients discontinued treatment for the entire population, a reduction in monthly headache days compared with baseline was reported at month 3, with a significant median [interquartile range] reduction in monthly headache days (- 9.0 [11.5], p < 0.001). A statistically different reduction was also reported at month 6 compared with baseline (- 10.0 [12.0]; p < 0.001) and at 12 months of treatment (- 10.0 [14.0]; p < 0.001). The percentage of patients with medication overuse was significantly reduced compared with baseline from 68.7% (57/83) to 29.6% (24/81), 25.3% (19/75), and 14.7% (10/68) at 3, 6, and 12 months of treatment, respectively (p < 0.001). Acute medication use (days and total number) and disability scores were also significantly reduced (p < 0.001). A ≥ 50% response rate was achieved for 51.9, 67.9, and 76.5% of all patients at 3, 6, and 12 months, respectively. Last observation carried forward analyses confirmed these findings. Fremanezumab was well tolerated, with just one patient discontinuing treatment because of adverse events. CONCLUSIONS This study provides evidence for the real-world effectiveness of fremanezumab in treating both high-frequency episodic migraine and chronic migraine, with meaningful and sustained improvements in multiple migraine-related variables. No new safety issue was identified.
Collapse
Affiliation(s)
- Valeria Caponnetto
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Antonio Russo
- Department of Advanced Medical and Surgical Sciences, Headache Centre, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Marcello Silvestro
- Department of Advanced Medical and Surgical Sciences, Headache Centre, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Alessandro Tessitore
- Department of Advanced Medical and Surgical Sciences, Headache Centre, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Roberto De Icco
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- Headache Science and Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Gloria Vaghi
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- Headache Science and Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Grazia Sances
- Headache Science and Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Cristina Tassorelli
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- Headache Science and Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Carlo Baraldi
- Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, AOU Policlinico di Modena, Modena, Italy
| | - Flavia Lo Castro
- Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, AOU Policlinico di Modena, Modena, Italy
| | - Simona Guerzoni
- Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, AOU Policlinico di Modena, Modena, Italy
| | - Maria Pia Prudenzano
- Headache Center, Amaducci Neurological Clinic, Policlinico General Hospital, Bari, Italy
| | - Adriana Fallacara
- Headache Center, Amaducci Neurological Clinic, Policlinico General Hospital, Bari, Italy
| | - Martino Gentile
- Headache Center, Amaducci Neurological Clinic, Policlinico General Hospital, Bari, Italy
| | - Raffaele Ornello
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Agnese Onofri
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Andrea Burgalassi
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy
| | - Alberto Chiarugi
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy
- Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Francesco De Cesaris
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy
| | - Antonio Granato
- Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, School of Neurology, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy
| | | | - Marina De Tommaso
- Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Edoardo Mampreso
- Headache Centre, Neurology-Euganea, Padua Health Unit, Padua, Italy
| | - Paola Merlo
- Neurological Unit, Headache Centre, Humanitas Gavazzeni, Bergamo, Italy
| | - Gianluca Coppola
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy
| | - Stefania Battistini
- Neurology and Clinical Neurophysiology Unit, Headache Center, Siena University Hospital Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
| | | | - Innocenzo Rainero
- Department of Neuroscience "Rita Levi Montalcini", Headache Center, University of Torino, Torino, Italy
| | - Federica Nicoletta Sepe
- Neurology Department, Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - Giorgio Dalla Volta
- U.O. Neurologia, Headache Center Istituto Clinico "Città di Brescia", Gruppo San Donato Brescia, Brescia, Italy
| | - Simona Sacco
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - Pierangelo Geppetti
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy
- Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Luigi Francesco Iannone
- Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.
- Department of Health Sciences, University of Florence, Viale Pieraccini 6, Florence, Italy.
| |
Collapse
|
4
|
Mazzoleni V, Grassi M, Lodigiani C, Rasura M, Zedde M, Gandolfo C, Zini A, DeLodovici ML, Paciaroni M, Del Sette M, Toriello A, Musolino R, Calabrò RS, Bovi P, Giossi A, Adami A, Silvestrelli G, Cavallini A, Marcheselli S, Bonifati DM, Checcarelli N, Tancredi L, Chiti A, Giorli E, Pezzini D, Locatelli M, Bonacina S, Giacalone G, Volta GD, Magoni M, Cerrato P, Bignamini V, Micieli G, Melis M, Sanguigni S, Braga M, Padovani A, Pezzini A. Migraine and Cryptogenic Ischemic Stroke. Ann Neurol 2021; 89:627-629. [PMID: 33368551 DOI: 10.1002/ana.25996] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 12/10/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Valentina Mazzoleni
- Department of Clinical and Experimental Sciences, Neurological Clinic, University of Brescia, Brescia, Italy
| | - Mario Grassi
- Department of the Nervous System and Behavior Sciences, Unit of Medical and Genomic Statistics, University of Pavia, Pavia, Italy
| | - Corrado Lodigiani
- Thrombosis and Hemorrhagic Diseases Center, IRCCS Humanitas Clinical and Research Hospital, Rozzano-Milan, Italy
| | - Maurizia Rasura
- Stroke Unit, Saint Andrea Hospital, La Sapienza University, Rome, Italy
| | - Marialuisa Zedde
- SC Neurology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Carlo Gandolfo
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal-Child Sciences, University of Genoa, Genoa, Italy
| | - Andrea Zini
- IRCCS Institute of Neurological Sciences of Bologna, UOC Neurology and Metropolitan Stroke Network, Maggiore Hospital, Bologna, Italy
| | | | - Maurizio Paciaroni
- Stroke Unit, Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy
| | | | - Antonella Toriello
- UOC Neurology, San Giovanni e Ruggi d'Aragona, University of Salerno, Salerno, Italy
| | - Rossella Musolino
- Department of Neuroscience, Psychiatric and Anesthesiology Sciences, Neurological Clinic, University of Messina, Messina, Italy
| | | | - Paolo Bovi
- UO Neurology, Borgo Trento University Hospital, Verona, Italy
| | | | | | | | - Anna Cavallini
- Stroke Unit, IRCCS C. Mondino Foundation Institute, Pavia, Italy
| | - Simona Marcheselli
- Emergency Neurology and Stroke Unit, IRCCS Humanitas Clinical and Research Hospital, Rozzano-Milan, Italy
| | | | | | - Lucia Tancredi
- Neurological Clinic III, San Paolo University Pole, ASST Santi Paolo e Carlo, Milan, Italy
| | - Alberto Chiti
- Neurology, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - Elisa Giorli
- Neurology Unit, Sant' Andrea Hospital, La Spezia, Italy
| | - Debora Pezzini
- Department of Clinical and Experimental Sciences, Neurological Clinic, University of Brescia, Brescia, Italy
| | - Martina Locatelli
- Department of Clinical and Experimental Sciences, Neurological Clinic, University of Brescia, Brescia, Italy
| | - Sonia Bonacina
- Department of Clinical and Experimental Sciences, Neurological Clinic, University of Brescia, Brescia, Italy
| | | | | | - Mauro Magoni
- Stroke Unit, Vascular Neurology, Spedali Civili, Brescia, Italy
| | - Paolo Cerrato
- Department of Neuroscience, Stroke Unit, University of Torino, Torino, Italy
| | | | - Giuseppe Micieli
- Emergency Neurology, IRCCS C. Mondino Foundation Institute, Pavia, Italy
| | | | - Sandro Sanguigni
- Department of Neurology, Madonna del Soccorso Hospital, San Benedetto del Tronto, Italy
| | | | - Alessandro Padovani
- Department of Clinical and Experimental Sciences, Neurological Clinic, University of Brescia, Brescia, Italy
| | - Alessandro Pezzini
- Department of Clinical and Experimental Sciences, Neurological Clinic, University of Brescia, Brescia, Italy
| | | |
Collapse
|
5
|
Dalla Volta G, Marceglia S, Zavarise P, Antonaci F. Cathodal tDCS Guided by Thermography as Adjunctive Therapy in Chronic Migraine Patients: A Sham-Controlled Pilot Study. Front Neurol 2020; 11:121. [PMID: 32153497 PMCID: PMC7047836 DOI: 10.3389/fneur.2020.00121] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Accepted: 02/03/2020] [Indexed: 01/03/2023] Open
Abstract
Objective: To explore the efficacy of cathodal tDCS applied ipsilateral to the cold patch, as determined by thermographic evaluation, in the treatment of chronic migraine. Background: Transcranial direct current stimulation (tDCS) is a non-invasive and safe technique that modulates the activity of the underlying cerebral cortex. tDCS has been extensively tested as a possible treatment for chronic pain and migraine with controversial results mainly due to the different setting procedure and location of electrodes. Since the presence of a hypothermic patch region detected through thermography has been suggested as a possible support for headache diagnosis, this "cold patch" could considered as possible effective location for tDCS application. Methods: Forty-five patients with chronic migraine were randomized to receive either cathodal (25 patients) or sham tDCS, for 5 consecutive daily sessions plus a recall session after 1 month. Cathodal tDCS was delivered at 1.5 mA for 15 min in each session. Subjects were evaluated before treatment (baseline, T0), and after 10 (T10), 60 (T60), and 120 (T120) days after treatment. The number of attacks, duration of attacks, pain intensity, number of days with headache, and number of analgesics were collected at each time evaluation. Results: Patients in the tDCS group showed a significant improvement compared to the sham group, during the whole study period in the frequency of migraine attacks (tDCS vs. sham: -47.8 ± 50.1% vs. -14.2 ± 16.5%, p = 0.004), number of days with headache (tDCS vs. sham: -42.7 ± 65.4% vs. -11.3 ± 18.0%, p = 0.015), duration of attacks (tDCS vs. sham: -29.1 ± 43.4% vs. -7.5 ± 17.6%, p = 0.016), intensity of the pain during an attack (tDCS vs. sham -31.1 ± 36.9% vs. 8.3 ± 13.5%, p = 0.004), and number of analgesics (tDCS vs. sham -54.3 ± 37.4% vs. -16.0 ± 19.6%, p < 0.0001). Conclusion: Our results suggest that cathodal tDCS is an effective adjuvant technique in migraine provided that an individual correct montage of the electrodes is applied, according to thermographic investigation.
Collapse
Affiliation(s)
| | - Sara Marceglia
- Dipartimento di Ingegneria e Architettura, Università degli Studi di Trieste, Trieste, Italy
| | - Paola Zavarise
- Brescia Headache Center, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Fabio Antonaci
- Pavia Headache Center, C. Mondino National Institute of Neurology Foundation, IRCCS, University of Pavia, Pavia, Italy
| |
Collapse
|
6
|
Mainardi F, Maggioni F, Volta GD, Trucco M, Sances G, Savi L, Zanchin G. Prevalence of headache attributed to aeroplane travel in headache outpatient populations: An Italian multicentric survey. Cephalalgia 2019; 39:1219-1225. [DOI: 10.1177/0333102419843676] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Background To assess the prevalence of headache attributed to aeroplane travel (AH) in patients referred to Italian Headache Centres. Material and method 869 consecutive patients visiting six Italian headache centres during a 6 month-period (October 2013 to March 2014) were enrolled in the survey. Among them, 136 (15.6%) had never flown and therefore were excluded from the study. The remaining 733 patients (f = 586, m = 147; age 39.1 ± 17.3) were asked about the occurrence of headache attacks during flight; those who answered the question positively filled in a detailed questionnaire that allowed the features of the attacks to be defined. Results Headache attacks during the flight was reported by 34/733 subjects; four presented attacks fulfilling ICHD-3 beta (1) criteria for migraine without aura and therefore were not further considered. The features of the remaining 30 (4.0%; m = 18, f = 12, age 36.4 ± 7.3) completely fulfilled the ICHD-3 beta criteria for AH. In more detail, the pain was unilateral (fronto-orbital: n = 23; fronto-parietal: n = 7; without side-shift: n = 25, with side-shift: n = 5), lasting up to 30 min in 29 subjects. All the patients reported the pain as very severe or unbearable and landing as the phase of travel in which the attack appeared. In four cases, a postictal, milder, dull headache could last up to 24 hours. Accompanying symptoms were present in eight cases (restlessness: n = 5; conjunctival injection and tearing: n = 2; restlessness + ipsilateral conjunctival injection and tearing: n = 1). The fear of experiencing further attacks negatively affected the propensity for future flights in 90.0% of subjects (n = 27). In all the patients, AH onset did not coincide with the first flight experience. Concomitant migraine without aura was diagnosed in 24, tension-type headache in four, migraine without aura + tension-type headache in two cases; none suffered from cluster headache. Five subjects reported AH on each flight, 20 in > 50% of flights, five occasionally. Despite the severe intensity of the pain, only one third of this sample spontaneously reverted to a pharmacological treatment; the most useful strategy combines a decongestant nasal spray plus the intake of a simple analgesic 30 min before the estimated attack. Spontaneous manoeuvres were applied by 18 patients (Valsalva-like: n = 12; compression: n = 2; both manoeuvres: n = 4), more often without significant improvement. These data confirm our previous finding on the clinical features of AH. Conclusion AH was found in 4.0% of a multicentre, large sample of patients with flight experiences. Although limited to a sample of patients followed in six Italian headache centres, to the best of our knowledge these are the first epidemiological data on AH gathered by direct interview. If properly investigated, AH seems to be a not infrequent condition, which, when diagnosed, could probably be prevented in many cases.
Collapse
Affiliation(s)
- Federico Mainardi
- Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy
| | - Ferdinando Maggioni
- Headache Centre, Department of Neurosciences, University of Padua, Padua, Italy
| | | | - Marco Trucco
- Headache Centre, Department of Neurology, Santa Corona Hospital, Pietra Ligure, Italy
| | - Grazia Sances
- Headache Science Centre, IRCCS Mondino Foundation, Pavia, Italy
| | - Lidia Savi
- Headache Centre, University of Turin, Turin, Italy
| | - Giorgio Zanchin
- Headache Centre, Department of Neurosciences, University of Padua, Padua, Italy
| |
Collapse
|
7
|
Antonaci F, Rossi E, Voiticovschi-Iosob C, Dalla Volta G, Marceglia S. Frontal infrared thermography in healthy individuals and chronic migraine patients: Reliability of the method. Cephalalgia 2018; 39:489-496. [PMID: 29989426 DOI: 10.1177/0333102418788341] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND The use of frontal infrared thermography in the diagnosis of primary headaches provided scattering results due to measurement fluctuations and different types of headaches or research protocols. OBJECTIVE This study aims to assess the reliability of frontal infrared thermography in healthy individuals and provide a preliminary evaluation in chronic migraine patients using a commercial infrared thermal camera. METHODS Thermographic images were acquired in 20 controls and 15 patients at three consecutive time-points in two daily sessions. The Side Difference and Asymmetry Index parameters were defined. The reproducibility of the measurements, the correlation of Asymmetry Index and Side Difference with clinical evaluations and patient perceptions, and the ability of the parameters to discriminate between patients and controls were investigated. RESULTS We reported a good reproducibility of the measurements (Inter-class Correlation Coefficient > 0.75 and Coefficient of Variation < 13.4%), independent from external factors. The Side Difference was significantly different between patients and controls ( p < 0.001). The Asymmetry Index showed good correlation with the side of unilateral pain ( p = 0.0056). CONCLUSIONS Frontal infrared thermography can be used to quantify the difference between the right and the left side of frontal vascular changes in chronic migraine patients, provided that standardized conditions are satisfied.
Collapse
Affiliation(s)
- Fabio Antonaci
- 1 Headache Centre, C. Mondino National Institute of Neurology Foundation, IRCCS, Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Elena Rossi
- 2 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy.,3 Newronika srl, Milan, Italy
| | | | - Giorgio Dalla Volta
- 5 Unità Operativa Neurologia, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Sara Marceglia
- 6 Dipartimento di Ingegneria e Architettura, Università degli Studi di Trieste, Trieste, Italy
| |
Collapse
|
8
|
Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, Pizzocaro C, Lussignoli G, Geroldi C, Zanetti O, Cotelli MS, Turla M, Borroni B, Rozzini L, Mirabile D, Defanti C, Gennuso M, Prelle A, Gentile S, Morandi A, Vollaro S, Volta GD, Bianchetti A, Conti MZ, Cappuccio M, Carbone P, Bellandi D, Abruzzi L, Bettoni L, Villani D, Raimondi MC, Lanari A, Ciccone A, Facchi E, Di Fazio I, Rozzini R, Boffelli S, Manzoni L, Salvi GP, Cavaliere S, Belotti G, Avanzi S, Pasqualetti P, Muscio C, Padovani A, Frisoni GB. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurol 2016; 73:1417-1424. [DOI: 10.1001/jamaneurol.2016.3751] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Marina Boccardi
- LANVIE–Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland2Laboratory of Alzheimer’s Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Daniele Altomare
- Laboratory of Alzheimer’s Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy3Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Clarissa Ferrari
- Unit of Statistics, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Cristina Festari
- Laboratory of Alzheimer’s Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy3Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Ugo Paolo Guerra
- Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy
| | - Barbara Paghera
- Department of Nuclear Medicine, University of Brescia, Brescia, Italy
| | - Claudio Pizzocaro
- Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy
| | - Giulia Lussignoli
- Alzheimer’s Unit, Memory Clinic, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Cristina Geroldi
- Alzheimer’s Unit, Memory Clinic, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Orazio Zanetti
- Alzheimer’s Unit, Memory Clinic, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | | | - Marinella Turla
- Neurology Unit, Ospedale di Vallecamonica Esine, Brescia, Italy
| | - Barbara Borroni
- Centre for Aging Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Luca Rozzini
- Centre for Aging Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Dario Mirabile
- European Foundation Biomedical Research, Center of Excellence Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy
| | - Carlo Defanti
- European Foundation Biomedical Research, Center of Excellence Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy
| | | | | | - Simona Gentile
- Department of Rehabilitation, Fondazione Teresa Camplani, Casa di cura Ancelle della Carità, Cremona, Italy
| | - Alessandro Morandi
- Department of Rehabilitation, Fondazione Teresa Camplani, Casa di cura Ancelle della Carità, Cremona, Italy
| | - Stefano Vollaro
- Neurology Unit, Istituto Clinico Città di Brescia, Brescia, Italy
| | | | - Angelo Bianchetti
- Department of Medicine and Rehabilitation, Istituto Clinico Sant’Anna, Brescia, Italy
| | - Marta Zaffira Conti
- Hospice, Istituto Polifunzionale Sociosanitario Foundation Cardinal Giorgio Gusmini, Vertova, Bergamo, Italy
| | - Melania Cappuccio
- Hospice, Istituto Polifunzionale Sociosanitario Foundation Cardinal Giorgio Gusmini, Vertova, Bergamo, Italy
| | - Pasqualina Carbone
- Alzheimer Evaluation Unit, Istituto Ospedaliero di Sospiro Non-Profit Organization of Social Utility Foundation, Sospiro, Cremona, Italy
| | - Daniele Bellandi
- Alzheimer Evaluation Unit, Istituto Ospedaliero di Sospiro Non-Profit Organization of Social Utility Foundation, Sospiro, Cremona, Italy
| | - Luciano Abruzzi
- Neurology Unit, Istituti Ospedalieri di Cremona, Cremona, Italy
| | - Luigi Bettoni
- Neurology Unit, Istituti Ospedalieri di Cremona, Cremona, Italy
| | - Daniele Villani
- Alzheimer Evaluation Unit, Casa di Cura Figlie di S. Camillo, Cremona, Italy
| | | | | | | | - Emanuela Facchi
- Geriatric General Rehabilitation, Fondazione Richiedei, Palazzolo sull'Oglio, Brescia, Italy
| | - Ignazio Di Fazio
- Geriatric General Rehabilitation, Fondazione Richiedei, Palazzolo sull'Oglio, Brescia, Italy
| | - Renzo Rozzini
- Neurology Unit, Poliambulanza Foundation, Brescia, Italy
| | | | - Laura Manzoni
- Neuromotor and Cognitive Rehabilitation Center, Clinic Quarenghi, San Pellegrino Terme, Bergamo, Italy
| | - Giovanni Pietro Salvi
- Neuromotor and Cognitive Rehabilitation Center, Clinic Quarenghi, San Pellegrino Terme, Bergamo, Italy
| | - Sabina Cavaliere
- Alzheimer Evaluation Unit, Hospice Santa Maria Ausiliatrice Onlus Foundation, Bergamo, Italy
| | - Gloria Belotti
- Alzheimer Evaluation Unit, Hospice Santa Maria Ausiliatrice Onlus Foundation, Bergamo, Italy
| | - Stefano Avanzi
- Neuromotor Rehabilitation Medicine, Salvatore Maugeri Foundation Clinic of Work and Rehabilitation, Istituto di Ricovero e Cura a Carattere Scientifico, Castel Goffredo, Mantova, Italy
| | - Patrizio Pasqualetti
- Service of Medical Statistics and Information Technology, Fatebenefratelli Foundation for Health Research and Education, Rome, Italy
| | - Cristina Muscio
- Laboratory of Alzheimer’s Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy26Division of Neurology V–Neuropathology, Fondazione, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
| | - Alessandro Padovani
- Centre for Aging Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Giovanni B. Frisoni
- LANVIE–Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland2Laboratory of Alzheimer’s Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy27Memory Clinic, University Hospital of Geneva, Geneva, Switzerland
| | | |
Collapse
|
9
|
Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, Ferrari C, Guerra UP, Paghera B, Muscio C, Bianchetti A, Volta GD, Turla M, Cotelli MS, Gennuso M, Prelle A, Zanetti O, Lussignoli G, Mirabile D, Bellandi D, Gentile S, Belotti G, Villani D, Harach T, Bolmont T, Padovani A, Boccardi M, Frisoni GB. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 2016; 49:60-68. [PMID: 27776263 DOI: 10.1016/j.neurobiolaging.2016.08.019] [Citation(s) in RCA: 755] [Impact Index Per Article: 94.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Revised: 08/23/2016] [Accepted: 08/24/2016] [Indexed: 12/14/2022]
Abstract
The pathway leading from amyloid-β deposition to cognitive impairment is believed to be a cornerstone of the pathogenesis of Alzheimer's disease (AD). However, what drives amyloid buildup in sporadic nongenetic cases of AD is still unknown. AD brains feature an inflammatory reaction around amyloid plaques, and a specific subset of the gut microbiota (GMB) may promote brain inflammation. We investigated the possible role of the GMB in AD pathogenesis by studying the association of brain amyloidosis with (1) GMB taxa with pro- and anti-inflammatory activity; and (2) peripheral inflammation in cognitively impaired patients. We measured the stool abundance of selected bacterial GMB taxa (Escherichia/Shigella, Pseudomonas aeruginosa, Eubacterium rectale, Eubacterium hallii, Faecalibacterium prausnitzii, and Bacteroides fragilis) and the blood expression levels of cytokines (pro-inflammatory cytokines: CXCL2, CXCL10, interleukin [IL]-1β, IL-6, IL-18, IL-8, inflammasome complex (NLRP3), tumor necrosis factor-alpha [TNF-α]; anti-inflammatory cytokines: IL-4, IL-10, IL-13) in cognitively impaired patients with (n = 40, Amy+) and with no brain amyloidosis (n = 33, Amy-) and also in a group of controls (n = 10, no brain amyloidosis and no cognitive impairment). Amy+ patients showed higher levels of pro-inflammatory cytokines (IL-6, CXCL2, NLRP3, and IL-1β) compared with both controls and with Amy- patients. A reduction of the anti-inflammatory cytokine IL-10 was observed in Amy+ versus Amy-. Amy+ showed lower abundance of E. rectale and higher abundance of Escherichia/Shigella compared with both healthy controls (fold change, FC = -9.6, p < 0.001 and FC = +12.8, p < 0.001, respectively) and to Amy- (FC = -7.7, p < 0.001 and FC = +7.4, p = 0.003). A positive correlation was observed between pro-inflammatory cytokines IL-1β, NLRP3, and CXCL2 with abundance of the inflammatory bacteria taxon Escherichia/Shigella (rho = 0.60, p < 0.001; rho = 0.57, p < 0.001; and rho = 0.30, p = 0.007, respectively) and a negative correlation with the anti-inflammatory E. rectale (rho = -0.48, p < 0.001; rho = -0.25, p = 0.024; rho = -0.49, p < 0.001). Our data indicate that an increase in the abundance of a pro-inflammatory GMB taxon, Escherichia/Shigella, and a reduction in the abundance of an anti-inflammatory taxon, E. rectale, are possibly associated with a peripheral inflammatory state in patients with cognitive impairment and brain amyloidosis. A possible causal relation between GMB-related inflammation and amyloidosis deserves further investigation.
Collapse
Affiliation(s)
- Annamaria Cattaneo
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy; King's College London, Institute of Psychiatry, London, UK.
| | - Nadia Cattane
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy
| | - Samantha Galluzzi
- Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Stefania Provasi
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy
| | - Nicola Lopizzo
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy
| | - Cristina Festari
- Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Clarissa Ferrari
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy
| | - Ugo Paolo Guerra
- Nuclear Medicine, Poliambulanza Foundation, Istituto Ospedaliero, Brescia, Italy
| | - Barbara Paghera
- Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy
| | - Cristina Muscio
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy; European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy
| | - Angelo Bianchetti
- Department of Medicine and Rehabilitation, Istituto Clinico Sant'Anna, Brescia, Italy
| | | | - Marinella Turla
- Neurology Unit, Ospedale di Vallecamonica Esine, Brescia, Italy
| | | | | | | | - Orazio Zanetti
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy
| | - Giulia Lussignoli
- Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy
| | - Dario Mirabile
- European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy
| | - Daniele Bellandi
- Alzheimer Evaluation Unit, Istituto Ospedaliero di Sospiro ONLUS Foundation, Cremona, Italy
| | - Simona Gentile
- Department of Rehabilitation, Casa di Cura Ancelle della Carità, Cremona, Italy
| | - Gloria Belotti
- Alzheimer Evaluation Unit, Hospice Santa Maria Ausiliatrice ONLUS Foundation, Bergamo, Italy
| | - Daniele Villani
- Alzheimer Evaluation Unit, Casa di Cura Figlie di S. Camillo, Cremona, Italy
| | - Taoufiq Harach
- Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland
| | | | - Alessandro Padovani
- Neurology Unit, Department of Medical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Marina Boccardi
- Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Giovanni B Frisoni
- Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals, Geneva, Switzerland; Memory Clinic, University Hospitals and University of Geneva, Geneva, Switzerland
| |
Collapse
|
10
|
Altomare D, Ferrari C, Festari C, Muscio C, Zanetti O, Turla M, Defanti C, Prelle A, Gentile S, Volta GD, Padovani A, Frisoni GB, Boccardi M. IC‐P‐005: Does Clinical Use of Amyloid‐Pet Affect Physicians’ Beliefs on The Pathogenetic Role of Amyloid‐β and The Clinical Usage of Amyloid‐Pet? Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Daniele Altomare
- IRCCS FatebenefratelliBresciaItaly
- University of BresciaBresciaItaly
| | | | - Cristina Festari
- IRCCS FatebenefratelliBresciaItaly
- University of BresciaBresciaItaly
| | - Cristina Muscio
- IRCCS FatebenefratelliBresciaItaly
- Fondazione IRCCS Istituto NeurologicoMilanoItaly
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Dalla Volta G, Carli D, Zavarise P, Ngonga G, Vollaro S. P026. Pilot study on the use of coenzyme Q10 in a group of patients with episodic migraine without aura. J Headache Pain 2015; 16:A186. [PMID: 28132202 PMCID: PMC4759389 DOI: 10.1186/1129-2377-16-s1-a186] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
| | - Daniela Carli
- Brescia Headache Centre, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Paola Zavarise
- Brescia Headache Centre, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Gaelle Ngonga
- Brescia Headache Centre, Istituto Clinico Città di Brescia, Brescia, Italy
| | - Stefano Vollaro
- Brescia Headache Centre, Istituto Clinico Città di Brescia, Brescia, Italy
| |
Collapse
|
12
|
Rainero I, Rubino E, Gallone S, Zavarise P, Carli D, Boschi S, Fenoglio P, Savi L, Gentile S, Benna P, Pinessi L, Dalla Volta G. KCNK18 (TRESK) genetic variants in Italian patients with migraine. Headache 2015; 54:1515-22. [PMID: 25324165 DOI: 10.1111/head.12439] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/18/2014] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To evaluate the prevalence of KCNK18 gene mutations in a dataset of Italian migraineurs, with and without aura, and in healthy controls, and to investigate in silico the functional effects of the mutations. BACKGROUND A role for the KCNK18 gene encoding for TRESK, a member of the family of potassium channel, has been recently suggested in migraine with aura. METHODS We sequenced the KCNK18 gene in 425 migraineurs (255 with aura and 170 without aura) and 247 healthy controls. RESULTS Five genetic variants (R10G, C110R, Y163Y, S231P, and F372L) were found in 13 (5.1%) out of 255 migraine with aura patients, and 6 variants (R10G, D46D, C110R, Y163Y, S178T, and S231P) were identified in 12 (7.1%) out of 170 migraine without aura patients. In 2.8% of controls, the R10G and L20V substitutions were found. In silico analysis suggested that C110R, S178T, S231P, and F372L mutations may have potential damaging effect on channel function, whereas the remaining mutations may have low damaging effect. CONCLUSIONS Our study shows the presence of several KCNK18 gene mutations in both migraine with aura and migraine without aura. However, the precise role of this gene in migraine predisposition deserves further studies.
Collapse
Affiliation(s)
- Innocenzo Rainero
- Neurology I - Headache Center, Department of Neuroscience "Rita Levi Montalcini, University of Torino, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Dalla Volta G, Zavarise P, Ngonga G, Agosti C, Premi E, Padovani A. Response to “Transient Global Amnesia as a Presenting Aura or Epilepsy?”. Headache 2014; 54:1235-6. [DOI: 10.1111/head.12412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
| | - P. Zavarise
- U.O. Neurologia; Istituto Clinico Citta' di Brescia; Brescia Italy
| | - G. Ngonga
- U.O. Neurologia; Istituto Clinico Citta' di Brescia; Brescia Italy
| | - C. Agosti
- U.O. Neurologia; Istituto Clinico Citta' di Brescia; Brescia Italy
| | - E. Premi
- Clinica Neurologica; Universita' di Brescia; Brescia Italy
| | - A. Padovani
- Clinica Neurologica; Universita' di Brescia; Brescia Italy
| |
Collapse
|
14
|
Pezzini A, Grassi M, Lodigiani C, Patella R, Gandolfo C, Zini A, Musolino R, Calabrò RS, Bovi P, Adami A, DeLodovici ML, Del Zotto E, Rota LL, Rasura M, Del Sette M, Spalloni A, Giossi A, Volonghi I, Casoni F, Cerrato P, Costa P, Magoni M, Toriello A, Paciaroni M, Volta GD, Iacoviello L, Padovani A. Interaction between proatherosclerotic factors and right-to-left shunt on the risk of cryptogenic stroke: the Italian Project on Stroke in Young Adults. Heart 2012; 98:485-9. [DOI: 10.1136/heartjnl-2011-300970] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
15
|
Pezzini A, Del Zotto E, Giossi A, Volonghi I, Costa P, Dalla Volta G, Padovani A. The migraine-ischemic stroke relation in young adults. Stroke Res Treat 2010; 2011:304921. [PMID: 21197470 PMCID: PMC3005862 DOI: 10.4061/2011/304921] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2010] [Accepted: 11/22/2010] [Indexed: 11/20/2022] Open
Abstract
In spite of the strong epidemiologic evidence linking migraine and ischemic stroke in young adults, the mechanisms explaining this association remain poorly understood. The observation that stroke occurs more frequently during the interictal phase of migraine prompts to speculation that an indirect relation between the two diseases might exist. In this regard, four major issues might be considered which may be summarized as follows: (1) the migraine-ischemic stroke relation is influenced by specific risk factors such as patent foramen ovale or endothelial dysfunction and more frequent in particular conditions like spontaneous cervical artery dissection; (2) migraine is associated with an increased prevalence of cardiovascular risk factors; (3) the link is caused by migraine-specific drugs; (4) migraine and ischemic vascular events are linked via a genetic component. In the present paper, we will review epidemiological studies, discuss potential mechanisms of migraine-induced stroke and comorbid ischemic stroke, and pose new research questions.
Collapse
Affiliation(s)
- Alessandro Pezzini
- Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Piazzale Spedali Civili, 1, 25100 Brescia, Italy
| | - Elisabetta Del Zotto
- Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Brescia, 25100 Brescia, Italy
| | - Alessia Giossi
- Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Piazzale Spedali Civili, 1, 25100 Brescia, Italy
| | - Irene Volonghi
- Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Piazzale Spedali Civili, 1, 25100 Brescia, Italy
| | - Paolo Costa
- Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Piazzale Spedali Civili, 1, 25100 Brescia, Italy
| | - Giorgio Dalla Volta
- Unità di Neurologia, Istituto Clinico Città di Brescia, 25123 Brescia, Italy
| | - Alessandro Padovani
- Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Piazzale Spedali Civili, 1, 25100 Brescia, Italy
| |
Collapse
|
16
|
Borroni B, Alberici A, Grassi M, Turla M, Zanetti O, Bianchetti A, Dalla Volta G, Rozzini R, Gilberti N, Bellelli G, Padovani A. Is frontotemporal lobar degeneration a rare disorder? Evidence from a preliminary study in Brescia county, Italy. J Alzheimers Dis 2010; 19:111-6. [PMID: 20061630 DOI: 10.3233/jad-2010-1208] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Frontotemporal Lobar Degeneration (FTLD) has always been considered a rare disorder, but only a few epidemiologic studies are available. The aim of the present work was to ascertain all FTLD patients in a Northern Italy area from January 2001 to December 2008, and to estimate the disease prevalence. On the census day, 213 FTD patients were still alive, resulting in an overall prevalence of 17.6 per 100,000 inhabitants. The prevalence of FTLD in patients aged 45-65 years was 22 per 100,000 inhabitants (95% CI=17-27). The prevalence of FTLD was the highest in patients aged 66-75 (78 per 100,000 inhabitants, 95% CI=56-100), and it was still high over 75 years (54 per 100,000 inhabitants, 95% CI=36-69). FTLD is a more common form of dementia than previously recognized. Our results claimed that FTLD is not only an early-onset disorder, but it is frequent in advanced age as well.
Collapse
Affiliation(s)
- Barbara Borroni
- Department of Neurology, University of Brescia, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Alberici A, Borroni B, Manelli F, Griffini S, Zavarise P, Padovani A, Dalla Volta G. Topiramate weight loss in migraine patients. J Neurol Sci 2008; 278:64-5. [PMID: 19084843 DOI: 10.1016/j.jns.2008.11.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2008] [Revised: 11/18/2008] [Accepted: 11/19/2008] [Indexed: 11/16/2022]
Abstract
Topiramate (TPM) is generally recognized efficacious and safe in migraine prevention. A significant proportion of patients undergoing TPM administration may show weight loss. In epileptic subjects, high body mass index (BMI) was found to be predictive of weight loss under TPM therapy. We therefore aimed to study whether common clinical determinants may be associated to TPM weigh loss in migraine patients. In our clinical series, high BMI was not found a predictor of weight loss under TPM treatment. Unknown genetic and environmental factors that may determine the courses of weight loss under TPM therapy are still do be identified.
Collapse
Affiliation(s)
- Antonella Alberici
- Neurology Unit, Department of Medical and Surgical Sciences, University of Brescia, Italy.
| | | | | | | | | | | | | |
Collapse
|
18
|
Pezzini A, Grassi M, Del Zotto E, Giossi A, Monastero R, Dalla Volta G, Archetti S, Zavarise P, Camarda C, Gasparotti R, Magoni M, Camarda R, Padovani A. Migraine Mediates the Influence of
C677T MTHFR
Genotypes on Ischemic Stroke Risk With a Stroke-Subtype Effect. Stroke 2007; 38:3145-51. [DOI: 10.1161/strokeaha.107.491506] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Alessandro Pezzini
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Mario Grassi
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Elisabetta Del Zotto
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Alessia Giossi
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Roberto Monastero
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Giorgio Dalla Volta
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Silvana Archetti
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Paola Zavarise
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Cecilia Camarda
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Roberto Gasparotti
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Mauro Magoni
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Rosolino Camarda
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| | - Alessandro Padovani
- From Dipartimento di Scienze Mediche e Chirurgiche (A.P., M.M.), Stroke Unit, Neurologia Vascolare, Spedali Civili di Brescia, Brescia, Italia; Dipartimento di Scienze Sanitarie Applicate (M.G.), Sezione di Statistica Medica e Epidemiologia, Università di Pavia, Pavia, Italia; Dipartimento di Scienze Mediche e Chirurgiche (E.D.Z., A.G., A.P.), Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia; Dipartimento di Neuroscienze Cliniche (R.M., C.C., R.C.), Divisione di Neurologia e
| |
Collapse
|
19
|
Borroni B, Brambilla C, Liberini P, Rao R, Archetti S, Gipponi S, Volta GD, Padovani A. Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with aura. J Headache Pain 2006; 6:182-4. [PMID: 16362658 PMCID: PMC3452037 DOI: 10.1007/s10194-005-0179-9] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
In the present work, we
report that the functional serotonin
transporter gene promoter (5–HTTLPR) polymorphism is
involved in migraine pathogenesis.
The distribution of 5–HTTLPR
genotypes was significantly different
in MA patients (S/S vs. S/L vs.
L/L=32.7 vs. 42.3 vs. 25.0%), MO
patients (18.5 vs. 39.1 vs. 42.4%)
and CON (18.0 vs. 51.3 vs. 30.7%;
chi–square test, p<0.05). In 5–HTTLPR S/S carriers, the odds
ratio for MA risk was 2.60 (95%
confidence interval
[95%CI]=1.75–3.85) compared to
CON, and it was 2.14
(95%CI=1.42–3.21) compared to
MO. These data provide a further
insight on the complex genotypephenotype
relationship involved in
MA pathogenesis, and might eventually
result in new and individualised
prognostic and therapeutic
measures.
Collapse
Affiliation(s)
- Barbara Borroni
- Department of Neurology, University of Brescia, Piazza Spedali Civili 1, I-25100 Brescia, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Dalla Volta G, Guindani M, Zavarise P, Griffini S, Pezzini A, Padovani A. Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain 2006; 6:328-30. [PMID: 16362702 PMCID: PMC3452039 DOI: 10.1007/s10194-005-0223-9] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
A relationship between
migraine and patent foramen ovale
(PFO) has been observed in relatively
small series of patients so far.
Furthermore, the exact mechanism
underlying such an association
remains unknown. In the present
study we determined the prevalence
of PFO by contrast–enhanced transcranial
Doppler (TCD) in a group
of 260 patients with migraine with
aura (MA+), 74 patients with
migraine without aura (MA–), and
38 patients with cluster headache
(CH). One–hundred–sixty–one
MA+subjects (61.9%), 12 MA–subjects
(16.2%), and 14 CH–subjects
(36.8%) were PFO–carriers. The
association was independent on the
frequency of migraine attacks and
complexity of aura. Finally, among
the 15 patients who had a history of
at least one migraine attack occurring
during a Valsalva maneuver
only one subject turned out to be
PFO–carrier. Our findings confirm
previous observations of a link
between MA+, CH, and PFO. They
also suggest that such an association
is independent on migraine
clinical phenotype and is probably
unrelated to the pathogenic mechanism
of paradoxical embolism.
Collapse
|
21
|
Bonetti M, Fontana A, Cotticelli B, Volta GD, Guindani M, Leonardi M. Intraforaminal O(2)-O(3) versus periradicular steroidal infiltrations in lower back pain: randomized controlled study. AJNR Am J Neuroradiol 2005; 26:996-1000. [PMID: 15891150 PMCID: PMC8158626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2004] [Accepted: 08/19/2004] [Indexed: 05/02/2023]
Abstract
BACKGROUND AND PURPOSE Reports about steroids and oxygen-ozone therapy to treat lower back pain have been increasing. The purpose of our study was to compare the clinical outcomes in patients treated with infiltrations of O(2)-O(3) gas or steroids at short-, medium-, and long-term follow-up. METHODS A total of 306 patients (166 with primarily disk disease, 140 with nondisk vertebral disease) with acute or chronic low back and sciatic nerve pain received a CT-guided intraforaminal infiltration of an O(2)-O(3) gas mixture or an periradicular infiltration of steroids. Neurologists unaware of the type of treatment assessed the patients. RESULTS At 1-week follow-up, most patients had a complete remission of pain, regardless of the treatment. At 6-month follow-up, differences in favor of O(2)-O(3) treatment were significant in patients with disk disease (P = .0021) but not in those without disk disease (P = .0992). Clinical outcomes were poor in 13 (15.1%) of 86 patients receiving O(2)-O(3) infiltration and in 18 (22.5%) of 80 patients receiving steroid injection (P = .2226). Among patients without disk disease, six (8.6%) of 70 patients receiving O(2)-O(3) infiltration but 21.4% of the patients receiving steroid injections had poor outcomes (P = .0332). CONCLUSION Oxygen-ozone treatment was highly effective in relieving acute and chronic lower back pain and sciatica. The gas mixture can be administered as a first treatment to replace epidural steroids.
Collapse
Affiliation(s)
- Matteo Bonetti
- Department of Neuroradiology and Division of Neurology, Istituto Clinico Città di Brescia, Italy
| | | | | | | | | | | |
Collapse
|